We have completed a third-party allotment of shares with Hiroaki Kitano and others as subscribers. As a result, our capital now stands at 14,980 thousand yen.
Related Articles
- Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of JapanEpistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
- Cell Culture Optimization Software 'CellTune Ver.2' Launches GloballyEpistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
- Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine SeminarOn June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.